CASTRO NETO, O. M.; http://lattes.cnpq.br/9633131454867774; CASTRO NETO, Ossian Maia de.
Resumen:
Kawasaki disease is a vasculitis that affects mainly pediatric patients, with a greater incidence
in the Asian continent, but present at a global level, with the most common and feared
complication being the formation of coronary aneurysms, a sequel that confers great
morbidity on the affected patients. can be avoided by an early diagnosis and initiation of the
correct treatment. recommended by the American Heart Association, treatment includes
specific intravenous immunoglobulin, in addition to aspirin in high doses. The aim of this
study was to evaluate whether the use of aspirin in high doses really has clinical relevance in
the treatment of Kawasaki Disease. As for the methodological design, an integrative review
was performed using the following databases as the research source: Latin American and
Caribbean Literature in Health Sciences (LILACS), International Medical Database Published
- Service of the US National Library of Medicine (PubMed) and Scientific Electronic Library
Online (Scielo). We used the descriptors Kawasaki disease, aspirin dose, ASA dose, coronary
aneurism, Kawasaki disease and aspirin dose, in addition to the Boolean operator AND. The
full-text articles available, free or paid, published in the last twenty years were selected. Eight
papers were selected at the end and studies that did not go into the treatment of the disease in
question were excluded. After analyzing the included studies, it was observed that aspirin in
high doses did not contribute to the prevention of coronary aneurysms in the short and
medium term, besides not reducing the duration of the fever, the resistance to the treatment or
the length of hospital stay. Adding to this is the fact that high doses of the drug can cause a
number of side effects, such as anemia, gastrointestinal and neurological disorders, and
delayed normalization of blood inflammatory markers. Thus, it is suggested that it is
necessary to review the prescription of high doses of aspirin as a mandatory practice in the
treatment of Kawasaki disease, as well as to promote a standardization of the treatment
protocols of the disease, which still present many divergences between the different
institutions, with supported by new studies on the subject.